Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azithromycin for prevention of recurrent acute lower respiratory infection in high-risk First Nations and Timorese children
ACTRN12619000456156Phase 3Active, not recruiting
- Sponsor
- Menzies School of Health Research
- Start
- Oct 2020
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 3, randomised, double-blind trial in pulmonary infection comparing Azithromycin with Placebo (2 arms). Primary endpoint: Rates of medically treated acute lower respiratory infections. Started Oct 2020; status: active, not recruiting.
02
Drugs
azithromycin
03
Conditions
pulmonary infection
Beyond the preview
Go deeper on ACTRN12619000456156.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12619000456156.